ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion

https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-the-lancet-302697632.html

https://x.com/i/status/2026984528708059527

https://x.com/i/status/2026984528708059527

ELI LILLY: SUBMITTED ORFORGLIPRON TO REGULATORS IN OVER 40 COUNTRIES, WITH POTENTIAL US ACTION FOR OBESITY IN Q2 2026

Nicht von mir, aber ich fand das witzig

When you have nothing else to compete on, you compete on price 😅😂

LLY - ELI LILLY SHARES QUICKLY DROPPED 2.5% IN PREMARKET AS 💊 Novo Nordisk $NVO to cut U.S. list prices

Mounjaro-Inhaltsstoff reduziert Alkoholkonsum: Forschungsergebnisse

https://thehill.com/policy/healthcare/5751372-tirzepatide-mounjaro-alcohol-study/

https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html?__source=iosappshare%7Ccom.apple.UIKit.activity.PostToTwitter

https://x.com/i/status/2025870689933410392

Novo Nordisk’s $NVO CagriSema MISSED its primary endpoint in the open-label REDEFINE 4 head-to-head vs Lilly’s $LLY Zepbound (tirzepatide) at 84 weeks. Weight loss was 23.0% with CagriSema vs 25.5% with tirzepatide on the “adhered to treatment” view, and 20.2% vs 23.6% on the treatment-regimen estimand (809 patients).